OCEANIUM, the UK-based seaweed biotechnology company developing next generation ingredients for people health and ocean health announces the appointment of Dr Sybille Buchwald-Werner as a Non-Executive Board Member.
Dr Buchwald-Werner is one of the most respected figures in the global nutraceutical industry, bringing more than 25 years of experience spanning pharmaceutical science, branded ingredient innovation, governance and international commercialisation.
A scientist by training with a strong entrepreneurial track record, she founded and scaled Vital Solutions GmbH into a globally recognised ingredient business, culminating in its successful acquisition in 2023.
Today, she is the owner of Newday, a platform translating scientific insight into strategies and solutions that create measurable business value, human wellbeing, and environmental impact.
Her appointment marks a significant milestone for OCEANIUM as the company accelerates commercial growth of OCEAN ACTIVES® H+, its high quality, seaweed derived gut health ingredient. OCEAN ACTIVES® H+ is designed to restore microbiome balance at micro-dose levels, delivering digestive benefits without the bloating or discomfort commonly associated with traditional prebiotics.
Dr Buchwald-Werner brings deep expertise in guiding companies from scientific concept through responsible scale-up, with a particular focus on governance, value chain integrity and long-term value creation. Her experience advising boards, investors and leadership teams across nutraceuticals, health tech and pharmaceuticals will support OCEANIUM as it expands partnerships with global brands and distributors.
Karen Scofield Seal, CEO and Co-Founder of OCEANIUM, said: “Dr Buchwald-Werner is widely recognised for her scientific credibility, commercial insight and principled leadership. Her decision to join our Board is a strong endorsement of both our science and our long-term vision. As we scale OCEAN ACTIVES® H+ internationally, her guidance will be invaluable in ensuring we grow with discipline, clarity and impact.”
Commenting on her appointment, Dr Buchwald-Werner said:
“OCEANIUM is a European circular seaweed platform where sustainable sourcing and green processing meet science-backed nutrition. I was drawn to the company’s women-founded leadership, its commitment to planetary and human health, and its ambition to build safe, responsible solutions at scale. This is the kind of innovation our industry needs to align long-term health with environmental stewardship.”
OCEANIUM develops high-value ingredients from sustainably farmed seaweed using proprietary, water-based processing. Its portfolio supports digestive health,
skin health and sustainable materials, while contributing to the growth of regenerative seaweed farming and six UN Sustainable Development Goals.
The appointment of Dr Buchwald-Werner further reinforces OCEANIUM’s position as an investor-ready business focused on building and scaling differentiated ingredients through a fully integrated, sustainable value chain for global health and nutrition markets.